What Biosyntia does

Biosyntia ApS is a Danish industrial biotechnology company founded in 2012 as a spin-out from the Centre for Biosustainability at the Technical University of Denmark. The company develops proprietary microbial fermentation processes that produce natural active ingredients—primarily vitamins (notably biotin/B7 and forskolin) and plant-derived bioactives—as sustainable, EU-sourced alternatives to chemical synthesis or plant extraction. Its commercial product portfolio comprises five fermentation-derived ingredients: BioB7 (biotin for nutrition and personal care), ForskoPro (forskolin for sports nutrition and skincare), CitriVive (anti-dandruff scalp active from upcycled citrus oil), Clarivance (monoterpenoid acne treatment), and EraGlow (liposomal ceramide-boosting skin care). The underlying platform, Biosynthetic Selections™, is a synthetic biology suite that enables ultra-high-throughput microbial engineering at a reported 40x cost reduction per microbe tested versus robotic alternatives, integrated with full value chain capabilities spanning strain engineering, fermentation optimization, downstream processing, scale-up, quality control, regulatory filing, and commercial-scale production.

Biosyntia operates as a B2B ingredient manufacturer, selling quote-based directly to consumer product companies in personal care, dietary supplements, food & beverage, and animal nutrition, with an enterprise sales motion anchored by industry trade show participation. Revenue is generated through ingredient sales and value-sharing co-development partnerships rather than fee-for-service research. Flagship strategic alliances include Givaudan (F&B flavors/fragrances, 2021) and WACKER Group (large-scale biotin production, 2022), with a co-development deal with Lantana Bio for flavonoid processes and a NATRUE certification obtained for CitriVive in 2025. The company has raised approximately €21.5M across pre-seed grants, a 2015 seed (Novo Seeds-led, DKK 12.5M), a 2018 Series A (€4M, Sofinnova and Novo Seeds), and a 2022 Series B led by ECBF at €11.5M initial close extended to €17.5M with Vækstfonden and Praesidium. Headquartered in Copenhagen with ~20 employees, the company is positioned in the personal care and nutraceutical end-markets where consumer demand for natural, sustainable, and traceable ingredients is replacing petrochemical and crop-extraction supply chains.

Name

Biosyntia

Legal name

Biosyntia ApS

Website

https://biosyntia.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Biosyntia is a Danish industrial biotech company that produces fermentation-derived natural active ingredients—vitamins, flavonoids, and bioactives—for B2B customers in personal care, nutrition, food & beverage, and animal nutrition.

Ownership category

akta.pro rank

Product category

Bio-based Active Ingredients (Fermentation-Derived Vitamins and Bioactives)

NAICS

Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

akta.pro secondary industries

Bio-based Food & Flavor Ingredients (Non-fuel Co-products: sweeteners, organic acids, flavors) (EUAAAIAJ), Biochemicals & Bio-based Platform Chemicals (cellulose sugars, lignin derivatives, organic acids) (IMAMALAB)

Keywords

• Microbial fermentation ingredients
• Bio-based vitamins
• Natural personal care actives
• Synthetic biology bioprocesses
• Nutraceutical ingredients

Headquarters

HQ city

Hørsholm

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Ingredient Sales: Biosyntia sells its proprietary fermentation-produced ingredients (vitamins and active ingredients) directly to B2B customers in personal care, human and animal nutrition industries. Revenue is generated through ingredient sales with pricing based on volume and specifications. The company operates as a B2B ingredient manufacturer selling to consumer product companies worldwide.
2. Partnership-based Development: Partnership arrangements based on value-sharing where Biosyntia develops full fermentation processes to deliver final ingredients to partners. Revenue derived from development collaboration and ingredient supply agreements with strategic partners.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Biosyntia develops and manufactures natural active ingredients through proprietary microbial fermentation processes for use in personal care, dietary supplements, food & beverage, and animal nutrition products. Its commercial portfolio includes BioB7 (biotin), ForskoPro (forskolin), CitriVive (anti-dandruff), Clarivance (acne treatment), and EraGlow (skin care), sold as B2B inputs to consumer-product manufacturers.

Product overview

Biosyntia is an industrial biotech company developing bio-based manufacturing processes for active ingredients used in beauty and nutrition. The company's product portfolio consists of fermentation-derived active ingredients: BioB7 (biotin/vitamin B7) available for both nutrition and personal care applications, ForskoPro (forskolin) serving sports nutrition and skin care, CitriVive (anti-dandruff active for scalp care), Clarivance (acne treatment ingredient), and EraGlow (ceramide-boosting skin care with liposomal delivery). These products are produced through proprietary microbial fermentation processes that replace fossil-based or extraction-based production methods, offering sustainable, natural, and EU-sourced alternatives for dietary supplements, personal care, food & beverage fortification, and animal nutrition.

Differentiator

Problem solved

Functional benefit

Brands

• BioB7: Natural and sustainably produced biotin (vitamin B7) via fermentation - marketed for nutrition, hair health, skin health, and beauty applications.
• ForskoPro
• CitriVive
• Clarivance
• EraGlow

Products and services

• BioB7 (Biotin / Vitamin B7) Natural and sustainably produced biotin (vitamin B7) created through microbial fermentation of plant-based carbohydrates; >98% pure D-biotin, EU-sourced and traceable, used in dietary supplements, multivitamins, and beauty supplements for hair, skin, and nail health.
• ForskoPro (Forskolin) Bio-based forskolin (a terpenoid that activates cAMP) produced via fermentation; purified to >95% active forskolin, EU-sourced, no batch-to-batch fluctuations; used in sports nutrition, weight management, eye health, and heart health applications.
• CitriVive Natural and sustainable anti-dandruff active ingredient derived from upcycled citrus oil through fermentation; combines anti-fungal, hydrating, antimicrobial, and soothing properties to restore scalp homeostasis in hair care formulations.
• Clarivance Next-generation acne ingredient, a fermentation-derived monoterpenoid from upcycled citrus oil; combines antibacterial, anti-inflammatory, sebum-regulating, and barrier-strengthening actions at just 1.25% concentration, outperforming azelaic acid by 2.5x on pore area reduction and 6x on pore number reduction.
• EraGlow Skin care active ingredient range featuring boosted performance and enhanced bioavailability through liposomal technology; based on natural fermentation-derived biotin with ceramide boosting, deep hydration, antioxidant, and melanin control properties; Natural Origin INDEX of 1 (ISO 16128).

Quantifiable outcome

• 48% reduction in CO2 equivalent; Avoiding 37kg of hazardous chemicals per 1 kg fermented Biotin
• +3 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• WACKER GroupflagshipStrategic or Co-development Partner · 11 January 2022Biosyntia and WACKER Group signed a multi-year contract to develop a large-scale, sustainable production process for fermentation-based biotin. WACKER brings strong expertise in biotechnological process development and industrial-scale fermentation, along with deep understanding of requirements and regulations of the food and nutraceutical industry. The partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative.
• Lantana BiocoreStrategic or Co-development Partner · 1 December 2021Biosyntia and French Lantana Bio signed an in-licensing deal to jointly develop production processes for flavonoids. Biosyntia responsible for bringing processes into production and commercializing the ingredients. This expands their development pipeline of nutraceutical ingredients with a wide array of possible uses.
• GivaudanflagshipStrategic or Co-development Partner · 1 September 2021Biosyntia signed a collaboration agreement with market leader Givaudan focused on the development and manufacture of sustainable, natural ingredients for food and beverage. Givaudan is the global leader in flavours and fragrances with 250+ years of heritage. The collaboration enables Givaudan to launch flavor ingredients that are both natural and sustainable.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Peers

• Evolva:

Direct peers

• Conagen: US-based synthetic biology company producing fermentation-derived ingredients for nutrition, beauty, food, and pharma — directly comparable to Biosyntia in technology platform and end-market focus, with a similar ingredient-out-licensing model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biosyntia-aps

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biosyntia